* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Straumann Holding AG's PEG Ratio or its related term are showing as below:
XSWX:STMN'
s PEG Ratio Range Over the Past 10 Years
Min: 1.1 Med: 2.79 Max: 8.2
Current: 4.47
During the past 13 years, Straumann Holding AG's highest PEG Ratio was 8.20. The lowest was 1.10. And the median was 2.79.
XSWX:STMN's PEG Ratio is ranked worse than 76.23% of 244
companies
in the Medical Devices & Instruments industry
Industry Median: 1.935
vs XSWX:STMN: 4.47
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Straumann Holding AG PEG Ratio Historical Data
The historical data trend for Straumann Holding AG's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Straumann Holding AG's PEG Ratio
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG's PEG Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's PEG Ratio falls into.
Straumann Holding AG PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Straumann Holding AG (XSWX:STMN) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Straumann Holding AG PEG Ratio Related Terms
Thank you for viewing the detailed overview of Straumann Holding AG's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Straumann Holding AG (XSWX:STMN) Business Description
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company's core products are dental implants, and it holds roughly 30% of the global implant dentistry market, which is estimated to be worth roughly CHF 5.4 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:STMN has been successfully added to your 